• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Dentsply Sirona Reports First Quarter 2025 Results

    5/8/25 6:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care
    Get the next $XRAY alert in real time by email
    • Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impact
    • GAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per share
    • Adjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, adjusted EPS of $0.43
    • Maintaining FY25 outlook for organic sales and adjusted EPS; increasing reported sales due to F/X changes

    CHARLOTTE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the first quarter of 2025.

    First quarter net sales of $879 million decreased (7.7%) (organic sales decreased (4.4%)) compared to the first quarter of 2024. Foreign currency changes negatively impacted first quarter 2025 net sales by approximately ($30) million. Net income was $20 million, or $0.10 per share, compared to a net income of $18 million, or $0.09 per share in the first quarter of 2024. Adjusted earnings per diluted share were $0.43, compared to $0.42 in the first quarter of 2024. A reconciliation of Non-GAAP measures (including organic sales, adjusted EBITDA and margin, adjusted EPS, adjusted free cash flow conversion, and segment adjusted operating income) to GAAP measures is provided below.

    "In the first quarter, organic sales were roughly flat excluding the Byte sales impact, with growth in two of our three regions. Adjusted EBITDA margin expanded which primarily reflects the benefits from our transformational initiatives and internal financial discipline. We are delivering progress through customer-centric innovation, customer experience improvements, and operational efficiency, while operating in an increasingly uncertain macroeconomic environment," said Simon Campion, President and Chief Executive Officer. "Looking forward, we are maintaining our outlook for organic sales and adjusted EPS and will continue to focus on improving what is within our control to deliver sustainable long-term performance."

    Q1 25 Summary Results (GAAP)

    (in millions, except per share amount and percentages) Q1 25Q1 24YoY
         
    Net Sales $879$953(7.7%)
    Gross Profit $466$506(7.9%)
    Gross Margin 53.0%53.1% 
    Net Income Attributable to Dentsply Sirona $20$18NM
    Diluted Earnings Per Share $0.10$0.09NM

    Q1 25 Summary Results (Non-GAAP)[1]

    (in millions, except per share amount and percentages) Q1 25Q1 24YoY
         
    Net Sales $879$953(7.7%)
    Organic Sales Growth %   (4.4%)
    Adjusted Gross Profit $495$540(8.3%)
    Adjusted Gross Margin 56.3%56.6% 
    Adjusted EBITDA $168$1604.2%
    Adjusted EBITDA Margin 19.0%16.8% 
    Adjusted EPS $0.43$0.423.7%

    NM - not meaningful

    Percentages are based on actual values and may not reconcile due to rounding.

    [1] Organic sales growth, adjusted gross profit, adjusted EBITDA, and adjusted EPS are Non-GAAP financial measures which exclude certain items. Please refer to "Non-GAAP Financial Measures" below for a description of these measures and to the tables at the end of this release for a reconciliation between GAAP and Non-GAAP measures.

    Q1 25 Segment Results

      Net Sales Growth % Organic Sales Growth %
         
    Connected Technology Solutions (4.7%) (0.5%)
    Essential Dental Solutions (2.7%) 0.4%
    Orthodontic and Implant Solutions (20.0%) (17.7%)
    Wellspect Healthcare 3.4% 8.0%
    Total (7.7%) (4.4%)

    Q1 25 Geographic Results

      Net Sales Growth % Organic Sales Growth %
         
    United States (15.2%) (14.9%)
    Europe (3.4%) 1.1%
    Rest of World (2.8%) 3.1%
    Total (7.7%) (4.4%)



    Cash Flow and Liquidity

    Operating cash flow in the first quarter of 2025 was $7 million, compared to $25 million in the first quarter of 2024, primarily due to the unfavorable timing of collections on accounts receivable and a build of inventory during the quarter. In the first quarter of 2025, the Company paid $32 million in dividends. The Company had $398 million of cash and cash equivalents as of March 31, 2025.

    2025 Outlook

    The Company is maintaining its 2025 outlook for organic sales in the range of down (4.0%) to (2.0%), and adjusted EPS in the range of $1.80 to $2.00. The Company is increasing its expected reported sales to a new range of $3.60 billion to $3.70 billion due to changes in foreign exchange rates. This outlook reflects the current state of tariffs and trade policy.

    Other 2025 outlook assumptions are included in the first quarter 2025 earnings presentation posted on the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. The Company does not provide forward-looking estimates on a GAAP basis as certain information, which may include, but is not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items, is not available without unreasonable effort and cannot be reasonably estimated. The exact amounts of these charges or credits are not currently determinable but may be significant.

    Conference Call/Webcast Information

    Dentsply Sirona's management team will host an investor conference call and live webcast on May 8th, 2025, at 8:30 am ET. A live webcast of the investor conference call and a presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com.

    For those planning to participate on the call, please register at https://register-conf.media-server.com/register/BIb73584ce1e6f4d81b57af1bfbeec6816. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call.

    About Dentsply Sirona

    Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide, high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona's headquarters is located in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

    Contact Information:

    Investors:

    Andrea Daley

    Vice President, Investor Relations

    +1-704-591-8631

    [email protected]

    Press:

    Marion Par-Weixlberger

    Vice President, Public Relations & Corporate Communications

    +43 676 848414588

    [email protected]

    Forward-Looking Statements and Associated Risks

    All statements in this Press Release that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, "Risk Factors" of the Company's most recent Annual Report on Form 10-K, and any updating information or other factors which may be described in the Company's other filings with the Securities and Exchange Commission (the "SEC"). No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Press Release or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.

    DENTSPLY SIRONA INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (in millions, except per share amounts)

    (unaudited)

     Three Months Ended March 31,
      2025   2024 
    Net sales$879  $953 
    Cost of products sold 413   447 
        
    Gross profit 466   506 
        
    Selling, general, and administrative expenses 358   415 
    Research and development expenses 36   42 
    Intangible asset impairments —   6 
    Restructuring and other costs 9   1 
        
    Operating income 63   42 
        
    Other income and expenses:   
    Interest expense, net 19   18 
    Other (income) expense, net —   (7)
        
    Income before income taxes 44   31 
    Provision for income taxes 25   14 
        
    Net income 19   17 
        
    Less: Net loss attributable to noncontrolling interest (1)  (1)
        
    Net income attributable to Dentsply Sirona$20  $18 
        
    Earnings per common share attributable to Dentsply Sirona:   
    Basic$0.10  $0.09 
    Diluted$0.10  $0.09 
        
    Weighted average common shares outstanding:   
    Basic 199.1   207.4 
    Diluted 199.8   208.5 
            

    DENTSPLY SIRONA INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in millions, except share and per share amounts)

    (unaudited)

     March 31, 2025 December 31, 2024
        
    Assets   
    Current Assets:   
    Cash and cash equivalents$398 $272
    Accounts and notes receivable-trade, net 604  556
    Inventories, net 612  564
    Prepaid expenses and other current assets 364  354
    Total Current Assets 1,978  1,746
        
    Property, plant, and equipment, net 791  766
    Operating lease right-of-use assets, net 133  136
    Identifiable intangible assets, net 1,212  1,207
    Goodwill 1,632  1,597
    Other noncurrent assets 304  301
    Total Assets$6,050 $5,753
        
    Liabilities and Equity   
    Current Liabilities:   
    Accounts payable$276 $241
    Accrued liabilities 738  754
    Income taxes payable 37  45
    Notes payable and current portion of long-term debt 742  549
    Total Current Liabilities 1,793  1,589
        
    Long-term debt 1,593  1,586
    Operating lease liabilities 88  91
    Deferred income taxes 134  129
    Other noncurrent liabilities 432  415
    Total Liabilities 4,040  3,810
        
    Total Equity 2,010  1,943
        
    Total Liabilities and Equity$6,050 $5,753
        

    DENTSPLY SIRONA INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in millions)

    (unaudited)

     Three Months Ended March 31,
      2025   2024 
        
    Cash flows from operating activities:   
    Net income$19  $17 
        
    Adjustments to reconcile net loss to net cash provided by operating activities:   
    Depreciation 34   32 
    Amortization of intangible assets 45   54 
    Indefinite-lived intangible asset impairment —   6 
    Deferred income taxes 1   (9)
    Stock-based compensation expense 10   11 
    Other non-cash expense 9   19 
    Changes in operating assets and liabilities:   
    Accounts and notes receivable-trade, net (31)  27 
    Inventories, net (26)  (5)
    Prepaid expenses and other current assets (1)  (28)
    Other noncurrent assets 4   (6)
    Accounts payable 14   (28)
    Accrued liabilities (44)  (50)
    Income taxes (12)  (2)
    Other noncurrent liabilities (15)  (13)
    Net cash provided by operating activities 7   25 
        
    Cash flows from investing activities:   
    Capital expenditures (19)  (34)
    Cash received on derivative contracts 1   — 
    Cash paid on derivative contracts —   (9)
    Proceeds from sale of property, plant, and equipment 1   — 
    Net cash used in investing activities (17)  (43)
        
    Cash flows from financing activities:   
    (Repayments) proceeds on short-term borrowings, net (272)  23 
    Proceeds from 364-day bridge loan 435   — 
    Cash dividends paid (32)  (29)
    Repayments on long-term borrowings (2)  (3)
    Cash paid for deferred financing costs (3)  — 
    Other financing activities, net (3)  (5)
    Net cash provided by (used in) financing activities 123   (14)
    Effect of exchange rate changes on cash and cash equivalents 13   (11)
    Net increase (decrease) in cash and cash equivalents 126   (43)
    Cash and cash equivalents at beginning of period 272   334 
    Cash and cash equivalents at end of period$398  $291 
        
    Supplemental disclosures of cash flow information:   
    Interest paid, net of amounts capitalized$13  $15 
    Non-cash investing activities:   
    Property, plant and equipment in accounts payable at end of period$22  $24 
    Exchange of inventory for naming and other rights$14  $— 

    Non-GAAP Financial Measures

    In addition to results determined in accordance with U.S. generally accepted accounting principles ("US GAAP"), the Company provides certain measures in this press release, described below, which are not calculated in accordance with US GAAP and therefore represent Non-GAAP measures. These Non-GAAP measures are used by the Company to measure its performance and may differ from those used by other companies. These Non-GAAP measures should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.

    Management believes that these Non-GAAP measures are helpful as they provide a measure of the results of operations, and are frequently used by investors and analysts to evaluate the Company's performance exclusive of certain items that impact the comparability of results from period to period, and which may not be indicative of past or future performance of the Company.

    Organic Sales

    The Company defines "organic sales" as the reported net sales adjusted for: (1) net sales from acquired businesses recorded prior to the first anniversary of the acquisition; (2) net sales attributable to disposed businesses in both the current and prior year periods; and (3) the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates.

    Adjusted Operating Income and Margin

    Adjusted operating income is computed by excluding the following items from operating income (loss) as reported in accordance with US GAAP:

    (1) Business combination-related costs and fair value adjustments. These adjustments include costs related to consummating and integrating acquired businesses, as well as net gains and losses related to disposed businesses. In addition, this category includes the post-acquisition roll-off of fair value adjustments recorded related to business combinations, except for amortization expense of purchased intangible assets noted below. Although the Company is regularly engaged in activities to find and act on opportunities for strategic growth and enhancement of product offerings, the costs associated with these activities may vary significantly between periods based on the timing, size and complexity of acquisitions and as such may not be indicative of past and future performance of the Company.

    (2) Restructuring-related charges and other costs. These adjustments include costs related to the implementation of restructuring initiatives, including but not limited to, severance costs, facility closure costs, and lease and contract termination costs, as well as related professional service costs associated with these restructuring initiatives and global transformation activity. The Company is continually seeking to take actions that could enhance its efficiency; consequently, restructuring charges may recur but are subject to significant fluctuations from period to period due to the varying levels of restructuring activity, and as such may not be indicative of past and future performance of the Company. Other costs include gains and losses on the sale of property, legal settlements, executive separation costs, write-offs of inventory as a result of product rationalization, and changes in accounting principles recorded within the period. This category also includes costs related to investigations and associated legal cases and remediation activities, which primarily include legal, accounting and other professional service fees, as well as turnover and other employee-related costs.

    (3) Goodwill and intangible asset impairments. These adjustments include charges related to goodwill and intangible asset impairments.

    (4) Amortization of purchased intangible assets. This adjustment excludes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value. Although these costs contribute to revenue generation and will recur in future periods, their amounts are significantly impacted by the timing and size of acquisitions, and as such may not be indicative of the future performance of the Company.

    (5) Fair value and credit risk adjustments. These adjustments include the non-cash mark-to-market changes in fair value associated with pension assets and obligations, the credit risk component of hedging instruments, and equity-method investments. Although these adjustments are recurring in nature, they are subject to significant fluctuations from period to period due to changes in the underlying assumptions and market conditions. The non-service component of pension expense is a recurring item, however it is subject to significant fluctuations from period to period due to changes in actuarial assumptions, interest rates, plan changes, settlements, curtailments, and other changes in facts and circumstances. As such, these items may not be indicative of past and future performance of the Company.

    Adjusted operating margin is calculated by dividing adjusted operating income by net sales.

    Adjusted Gross Profit and Margin

    Adjusted gross profit is computed by excluding from gross profit the impact of any of the above adjustments that affect either sales or cost of sales.

    Adjusted gross margin is calculated by dividing adjusted gross profit by net sales.

    Adjusted Net Income (Loss)

    Adjusted net income (loss) consists of net income (loss) as reported in accordance with US GAAP, adjusted to exclude the items identified above, as well as the related income tax impacts of those items. The income tax effect of each pre-tax adjustment was determined based on the tax rate of the jurisdiction in which the related pre-tax adjustment was recorded.

    Additionally, net income is adjusted for other tax-related adjustments such as discrete or significant adjustments to valuation allowances and other uncertain tax positions, final settlement of income tax audits, discrete tax items resulting from the implementation of restructuring initiatives, the windfall or shortfall relating to exercise of employee stock-based compensation, any difference between the interim and annual effective tax rate, and adjustments relating to prior periods.

    Management believes that these adjustments for certain tax-related matters are helpful to normalize the tax effects of certain discrete or significant items that are irregular or infrequent in timing and may not be indicative of past or future performance of the Company.

    Adjusted EBITDA and Margin

    In addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization.

    Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net sales.

    Adjusted Earnings (Loss) Per Diluted Share

    Adjusted earnings (loss) per diluted share (adjusted EPS) is computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona stockholders by the diluted weighted average number of common shares outstanding.

    Adjusted Free Cash Flow and Conversion

    The Company defines adjusted free cash flow as net cash provided by operating activities minus capital expenditures during the same period, and adjusted free cash flow conversion is defined as adjusted free cash flow divided by adjusted net income (loss). Management believes this Non-GAAP measure is important for use in evaluating the Company's financial performance as it measures our ability to efficiently generate cash from our business operations relative to earnings. It should be considered in addition to, rather than as a substitute for, net income (loss) as a measure of our performance or net cash provided by operating activities as a measure of our liquidity.

    DENTSPLY SIRONA INC. AND SUBSIDIARIES

    (In millions, except percentages)

    (unaudited)

    A reconciliation of reported net sales to organic sales by geographic region is as follows:

      Three Months Ended March 31, 2025 Q1 2025 Change Three Months Ended March 31, 2024
    (in millions, except percentages) U.S.EuropeROWTotal U.S.EuropeROWTotal U.S.EuropeROWTotal
                    
    Net sales $302$362$215$879 (15.2%)(3.4%)(2.8%)(7.7%) $356$376$221$953
    Foreign exchange impact      (0.3%)(4.5%)(5.9%)(3.3%)     
    Organic sales      (14.9%)1.1%3.1%(4.4%)     
                        

    Percentages are based on actual values and may not reconcile due to rounding.

    A reconciliation of reported net sales to organic sales by segment is as follows:

      Three Months Ended March 31, 2025 Q1 2025 Change Three Months Ended March 31, 2024
    (in millions, except percentages) Connected Technology SolutionsEssential Dental SolutionsOrthodontic and Implant SolutionsWellspect HealthcareTotal Connected Technology SolutionsEssential Dental SolutionsOrthodontic and Implant SolutionsWellspect HealthcareTotal Connected Technology SolutionsEssential Dental SolutionsOrthodontic and Implant SolutionsWellspect HealthcareTotal
                       
    Net sales $235$353$217$74$879 (4.7%)(2.7%)(20.0%)3.4%(7.7%) $247$364$271$71$953
    Foreign exchange impact       (4.2%)(3.1%)(2.3%)(4.6%)(3.3%)      
    Organic sales       (0.5%)0.4%(17.7%)8.0%(4.4%)      
                            

    Percentages are based on actual values and may not reconcile due to rounding.



    DENTSPLY SIRONA INC. AND SUBSIDIARIES

    (In millions, except percentages)

    (unaudited)

    The Company's segment adjusted operating income for the three months ended March 31, 2025 and 2024 was as follows:

      Three Months Ended March 31,
    (in millions)  2025  2024 
         
    Connected Technology Solutions $7 $2 
    Essential Dental Solutions  135  115 
    Orthodontic and Implant Solutions  37  42 
    Wellspect Healthcare  26  23 
    Segment adjusted operating income  205  182 
         
    Reconciling items expense (income):    
    All other (a)  87  79 
    Intangible asset impairments  —  6 
    Restructuring and other costs  9  1 
    Interest expense, net  19  18 
    Other (income) expense, net  —  (7)
    Amortization of intangible assets  45  54 
    Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations  1  — 
    Income before income taxes $44 $31 
            

    (a) Includes unassigned corporate headquarters costs.



    DENTSPLY SIRONA INC. AND SUBSIDIARIES

    (In millions, except percentages)

    (unaudited)

    For the three months ended March 31, 2025, a reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows:

    (in millions, except percentages and per share data) Gross Profit Operating

    income
     Net Income

    Attributable to

    Dentsply Sirona

    (a)
     Diluted EPS
    GAAP $466  $63  $20 $0.10
    Non-GAAP Adjustments:        
    Amortization of Purchased Intangible Assets  28   45   33  0.16
    Restructuring-Related Charges and Other Costs  —   25   19  0.10
    Business Combination-Related Costs and Fair Value Adjustments  1   1   1  —
    Income Tax-Related Adjustments  —   —   14  0.07
    Adjusted Non-GAAP $495  $134  $87 $0.43
    GAAP Margin  53.0%  7.1%    
    Adjusted Non-GAAP Margin  56.3%  15.1%    
             
    Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share  199.8
    Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share  199.8
    (a) The tax expense on the Non-GAAP adjustments totals $4 million which is inclusive of the $14 million income tax-related adjustment above.  

    Percentages are based on actual values and may not reconcile due to rounding.



    DENTSPLY SIRONA INC. AND SUBSIDIARIES

    (In millions, except percentages)

    (unaudited)

    For the three months ended March 31, 2024, a reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows:

    (in millions, except percentages and per share data) Gross Profit Operating

    income
     Net Income

    Attributable to

    Dentsply Sirona

    (a)
     Diluted EPS
    GAAP $506  $42  $18 $0.09
    Non-GAAP Adjustments:        
    Amortization of Purchased Intangible Assets  31   54   40  0.19
    Restructuring-Related Charges and Other Costs  3   17   13  0.06
    Goodwill and Intangible Asset Impairments  —   6   4  0.02
    Business Combination-Related Costs and Fair Value Adjustments  —   1   1  —
    Income Tax-Related Adjustments  —   —   11  0.06
    Adjusted Non-GAAP $540  $120  $87 $0.42
    GAAP Margin  53.1%  4.4%    
    Adjusted Non-GAAP Margin  56.6%  12.6%    
             
    Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share  208.5
    Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share  208.5
    (a) The tax expense on the Non-GAAP adjustments totals $9 million, which is inclusive of the $11 million income tax-related adjustment above.  

    Percentages are based on actual values and may not reconcile due to rounding.



    DENTSPLY SIRONA INC. AND SUBSIDIARIES

    (In millions, except percentages)

    (unaudited)

    A reconciliation of reported net income attributable to Dentsply Sirona to adjusted EBITDA and margin for the three months ended March 31, 2025 and 2024 is as follows:

      Three Months Ended March 31,
    (in millions, except percentages)  2025   2024 
         
    Net income attributable to Dentsply Sirona $20  $18 
    Interest expense, net  19   18 
    Income tax expense  25   14 
    Depreciation(1)  33   32 
    Amortization of purchased intangible assets  45   54 
    Restructuring-related charges and other costs  25   17 
    Goodwill and intangible asset impairments  —   6 
    Business combination-related costs and fair value adjustments  1   1 
    Adjusted EBITDA $168  $160 
         
    Net sales $879  $953 
    Adjusted EBITDA margin  19.0%  16.8%

    (1) Excludes those depreciation-related amounts which were included as part of the business combination-related adjustments and Restructuring-related charges and other costs.

    Percentages are based on actual values and may not reconcile due to rounding.

    A reconciliation of adjusted free cash flow conversion for the three months ended March 31, 2025 and 2024 is as follows:

      Three Months Ended March 31,
    (in millions, except percentages)  2025   2024 
         
    Net cash provided by operating activities $7  $25 
    Capital expenditures  (19)  (34)
    Adjusted free cash flow $(12) $(9)
         
    Adjusted net income $87  $87 
    Adjusted free cash flow conversion  (14%)  (10%)

    Percentages are based on actual values and may not reconcile due to rounding.



    Primary Logo

    Get the next $XRAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XRAY

    DatePrice TargetRatingAnalyst
    4/15/2025$14.00Overweight → Equal-Weight
    Morgan Stanley
    3/13/2025Buy → Hold
    Needham
    2/14/2025$20.00Equal Weight
    Wells Fargo
    1/23/2025$30.00 → $20.00Buy → Hold
    Jefferies
    1/7/2025$20.00Outperform → In-line
    Evercore ISI
    12/4/2024$21.00Neutral
    Mizuho
    11/7/2024Outperform → Market Perform
    Leerink Partners
    10/25/2024$34.00 → $29.00Buy
    Needham
    More analyst ratings

    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dentsply Sirona Reports First Quarter 2025 Results

      Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impactGAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per shareAdjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, adjusted EPS of $0.43Maintaining FY25 outlook for organic sales and adjusted EPS; increasing reported sales due to F/X changes CHARLOTTE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the first quarter of 2025. First quarter net sales of $879 million decreased (7.7%) (organic sales decreased (4.4%)) compared to the first quarter of 2

      5/8/25 6:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona to Host First Quarter Conference Call on May 8th

      CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register-conf

      4/9/25 7:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader

      CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se

      3/17/25 8:45:57 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Financials

    Live finance-specific insights

    See more
    • Dentsply Sirona Reports First Quarter 2025 Results

      Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impactGAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per shareAdjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, adjusted EPS of $0.43Maintaining FY25 outlook for organic sales and adjusted EPS; increasing reported sales due to F/X changes CHARLOTTE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the first quarter of 2025. First quarter net sales of $879 million decreased (7.7%) (organic sales decreased (4.4%)) compared to the first quarter of 2

      5/8/25 6:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona to Host First Quarter Conference Call on May 8th

      CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register-conf

      4/9/25 7:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Reports Fourth Quarter and Full Year 2024 Results, Provides Full Year 2025 Outlook

      FY24 net sales of $3,793 million decreased (4.3%), organic sales decreased (3.5%) including a (1.2%) Byte sales impactFY24 GAAP net loss of ($910) million or ($4.48) per share, adjusted EPS of $1.67Q4 net sales of $905 million decreased (10.6%), organic sales decreased (10.7%) including a (6.0%) Byte sales impactQ4 GAAP net loss of ($430) million or ($2.16) per share, adjusted EPS of $0.26FY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (2.0%); adjusted EPS of $1.80 to $2.00(1) CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial resul

      2/27/25 6:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    SEC Filings

    See more
    • SEC Form 10-Q filed by DENTSPLY SIRONA Inc.

      10-Q - DENTSPLY SIRONA Inc. (0000818479) (Filer)

      5/8/25 9:13:52 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • DENTSPLY SIRONA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

      5/8/25 7:22:49 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by DENTSPLY SIRONA Inc.

      DEFA14A - DENTSPLY SIRONA Inc. (0000818479) (Filer)

      4/14/25 8:00:49 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Vergis Janet S. was granted 87 shares, increasing direct ownership by 0.29% to 30,101 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      4/15/25 4:29:05 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Director Varon Leslie F was granted 87 shares, increasing direct ownership by 0.26% to 33,807 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      4/15/25 4:25:53 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • EVP, Corp Dev, GC & Secretary Rosenzweig Richard C was granted 628 shares, increasing direct ownership by 0.76% to 83,452 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      4/15/25 4:24:07 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lucier Gregory T bought $249,994 worth of shares (15,142 units at $16.51), increasing direct ownership by 23% to 81,971 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      3/3/25 6:33:03 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Amendment: Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 8% to 66,730 units (SEC Form 4)

      4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      1/29/25 6:14:01 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 7% to 71,730 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      11/18/24 4:16:34 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dentsply Sirona downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Dentsply Sirona from Overweight to Equal-Weight and set a new price target of $14.00

      4/15/25 9:24:19 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona downgraded by Needham

      Needham downgraded Dentsply Sirona from Buy to Hold

      3/13/25 7:58:34 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Dentsply Sirona with a new price target

      Wells Fargo initiated coverage of Dentsply Sirona with a rating of Equal Weight and set a new price target of $20.00

      2/14/25 7:09:40 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

      SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      12/6/24 10:11:29 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

      SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      11/14/24 1:22:35 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

      SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      11/12/24 4:23:31 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader

      CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se

      3/17/25 8:45:57 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology
    • Dentsply Sirona Appoints Herman V. Cueto Interim Chief Financial Officer

      CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Herman V. Cueto, a seasoned healthcare executive, has been appointed Interim Chief Financial Officer, effective immediately. He brings over two decades of experience leading and working in finance organizations across the healthcare industry. Mr. Cueto will oversee the finance organization while Dentsply Sirona completes its ongoing search for the Company's next CFO. "We are fortunate to have Herman joining us as interim CFO during this important time in Dentsply Sirona's history," said Simon Campion, President and Chief Executive Officer. "Herman

      12/3/24 8:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care